Shares of US clinical-stage biotech Biohaven (NYSE: BHVN) rose 9.6% to $21.74 yesterday, after it announced an agreement with ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear ...

The biotech has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its spinocerebellar ...

Oberland Capital Management is pumping some new life into Biohaven, striking a unique investment deal worth up to $600 ...

A genetic signature including four genes in gastric cancer is linked to an increase in recurrence and mortality.

Early identification of individuals at a high risk for MASLD could “profoundly transform” intervention strategies, experts ...

If a company files for Chapter 7 bankruptcy, that means it's heading for liquidation, in which assets are sold off to pay creditors.

Pfizer Inc. stock hits a 12-year low due to M&A missteps and high debt. Click here to find out why I rate PFE stock a Hold.

The leading Migraine Companies such as ​ Satsuma Pharmaceuticals, Biohaven Pharmaceuticals, Allodynic Therapeutics, Vaxxinity ...